By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Nonsteroidal antiandrogen (NSAA) drug enzalutamide, marketed under the trade name Xtandi, is used to treat prostate cancer. For the treatment of metastatic castration-resistant prostate cancer , nonmetastatic castration-resistant prostate cancer, and metastatic castration-sensitive prostate cancer, it is advised to be used in conjunction with castration . It is consumed orally.
Enzalutamide can cause asthenia, back pain, diarrhoea, arthralgia, and hot flushes when castration is used with it. It can occasionally lead to seizures. The likelihood of medication interactions is very high.
As an antagonist of the androgen receptor, which is the biological target of androgens like testosterone and dihydrotestosterone, enzalutamide functions as an antiandrogen.
By doing this, it stops these hormones from having an impact on the prostate gland and other parts of the body.
The Global ENZULATAMIDE market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Astellas’ and Pfizer’s XTANDI (enzalutamide) Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 ARCHES .Before the European Society for Medical Oncology (ESMO) Congress, Astellas Pharma Inc. and Pfizer Inc.
reported that XTANDI (enzalutamide) enhanced overall survival (OS) in the ARCHES study in males with metastatic hormone-sensitive prostate cancer (mHSPC, also known as metastatic castration-sensitive prostate cancer).
XTANDI plus androgen deprivation therapy (ADT) was compared to placebo plus ADT in the Phase 3 randomised, double-blind, placebo-controlled trial for males with mHSPC, and OS was a significant secondary endpoint.
Comparing XTANDI plus ADT to a placebo plus ADT, the risk of death was lowered by 34%. In none of the therapy groups was the median OS, which measures the period of time from randomization to death from any cause, reached. The safety profile for weapons matched the core analysis’s conclusions.
The Journal of Clinical Oncology released the main findings from the ARCHES trial. The treatment with XTANDI with ADT indicated a 61% reduction in the risk of radiographic disease progression or mortality compared with ADT alone in males with mHSPC, according to its primary endpoint of radiographic progression-free survival (rPFS), as determined by independent central review.
In the ARCHES primary analysis, individuals receiving XTANDI plus ADT and those getting a placebo plus ADT experienced Grade 3 or higher adverse events at comparable rates. Hot flushes, fatigue, arthralgia, hypertension, nausea, musculoskeletal pain, diarrhoea, asthenia, and dizziness were common AEs that were reported more frequently in individuals treated with XTANDI with ADT than in those treated with ADT alone.
